Search - tctmd.com

Displaying 21 - 40 of 118

Sort: Relevancy | Date

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

Presentation ACC 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presenter: Michael J. Reardon

April 04, 2022

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Conference News ACC 2021

Cooling OHCA Patients to 31°C Not Superior to 34°C: CAPITAL-CHILL

Caitlin E. Cox

May 26, 2021

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

News Conference News ACC 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Yael L. Maxwell

May 15, 2021

News Conference News ACC 2021

Wide Variation in TAVI Readmission Rates Among US Hospitals

L.A. McKeown

May 07, 2021

News Conference News ACC 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

L.A. McKeown

April 07, 2020

News Conference News ACC 2020

New Patient-Focused TAVR Quality Score Rolling Out to US Hospitals

Michael O'Riordan

April 06, 2020

News Conference News ACC 2020

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

Michael O'Riordan

March 29, 2020

News Conference News ACC 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Yael L. Maxwell

March 29, 2020

News Conference News ACC 2020

UK TAVI: Real-world TAVR and SAVR Have Similar 1-Year Mortality

L.A. McKeown

March 29, 2020

News Conference News ACC 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

Todd Neale

March 29, 2020

News Conference News ACC 2020

Lower Risk of Death With Conscious Sedation in TAVR: TVT Registry

Michael O'Riordan

March 19, 2020

News Conference News ACC 2019

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

Shelley Wood

April 05, 2019

News Conference News ACC 2019

POET: Oral Antibiotics Continue to Show Good Long-term Results for Endocarditis

L.A. McKeown

March 18, 2019

News Conference News ACC 2019

TAVR in Bicuspid Aortic Stenosis Safe, Feasible in Selected Real-World Patients

Yael L. Maxwell

March 17, 2019

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

Advertisement

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Cooling OHCA Patients to 31°C Not Superior to 34°C: CAPITAL-CHILL

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Wide Variation in TAVI Readmission Rates Among US Hospitals

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

New Patient-Focused TAVR Quality Score Rolling Out to US Hospitals

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

UK TAVI: Real-world TAVR and SAVR Have Similar 1-Year Mortality

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

Lower Risk of Death With Conscious Sedation in TAVR: TVT Registry

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

POET: Oral Antibiotics Continue to Show Good Long-term Results for Endocarditis

TAVR in Bicuspid Aortic Stenosis Safe, Feasible in Selected Real-World Patients

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content